www.aspenpharma.com
Open in
urlscan Pro
151.101.66.159
Public Scan
Submitted URL: http://aspenpharma.com/
Effective URL: https://www.aspenpharma.com/
Submission: On January 26 via manual from US — Scanned from DE
Effective URL: https://www.aspenpharma.com/
Submission: On January 26 via manual from US — Scanned from DE
Form analysis
1 forms found in the DOMGET https://www.aspenpharma.com/
<form aria-label="Search" method="get" role="search" action="https://www.aspenpharma.com/" title="Type and press Enter to search.">
<input aria-label="Search" type="search" class="fl-search-input form-control" name="s" placeholder="Search" value="" onfocus="if (this.value === 'Search') { this.value = ''; }" onblur="if (this.value === '') this.value='Search';">
</form>
Text Content
logo * Consent * Details * [#IABV2SETTINGS#] * About THIS WEBSITE USES COOKIES We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. Consent Selection Necessary Preferences Statistics Marketing Show details Necessary 2 Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies. Cookiebot 1 Learn more about this provider CookieConsentStores the user's cookie consent state for the current domain Expiry: 1 yearType: HTTP www.aspenpharma.com 1 PHPSESSIDPreserves user session state across page requests. Expiry: SessionType: HTTP Preferences 2 Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in. Vimeo 2 Learn more about this provider playerSaves the user's preferences when playing embedded videos from Vimeo. Expiry: 1 yearType: HTTP sync_activeContains data on visitor's video-content preferences - This allows the website to remember parameters such as preferred volume or video quality. The service is provided by Vimeo.com. Expiry: PersistentType: HTML Statistics 6 Statistic cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. Issuu 2 Learn more about this provider sessionPageNumbersSets a unique ID for the session. This allows the website to obtain data on visitor behaviour for statistical purposes. Expiry: SessionType: HTML sessionStartTimeDetermines when the visitor last visited the different subpages on the website, as well as sets a timestamp for when the session started. Expiry: SessionType: HTML Vimeo 1 Learn more about this provider vuidCollects data on the user's visits to the website, such as which pages have been read. Expiry: 2 yearsType: HTTP www.aspenpharma.com 3 _gaRegisters a unique ID that is used to generate statistical data on how the visitor uses the website. Expiry: 2 yearsType: HTTP _gatUsed by Google Analytics to throttle request rate Expiry: 1 dayType: HTTP _gidRegisters a unique ID that is used to generate statistical data on how the visitor uses the website. Expiry: 1 dayType: HTTP Marketing 1 Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers. Issuu 1 Learn more about this provider iutkRecognises the user's device and what Issuu documents have been read. Expiry: 179 daysType: HTTP Unclassified 0 Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies. We do not use cookies of this type. Cross-domain consent[#BULK_CONSENT_DOMAINS_COUNT#] [#BULK_CONSENT_TITLE#] List of domains your consent applies to: [#BULK_CONSENT_DOMAINS#] Cookie declaration last updated on 29.12.21 by Cookiebot [#IABV2_TITLE#] [#IABV2_BODY_INTRO#] [#IABV2_BODY_LEGITIMATE_INTEREST_INTRO#] [#IABV2_BODY_PREFERENCE_INTRO#] [#IABV2_LABEL_PURPOSES#] [#IABV2_BODY_PURPOSES_INTRO#] [#IABV2_BODY_PURPOSES#] [#IABV2_LABEL_FEATURES#] [#IABV2_BODY_FEATURES_INTRO#] [#IABV2_BODY_FEATURES#] [#IABV2_LABEL_PARTNERS#] [#IABV2_BODY_PARTNERS_INTRO#] [#IABV2_BODY_PARTNERS#] Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages. You can at any time change or withdraw your consent from the Cookie Declaration on our website. Learn more about who we are, how you can contact us and how we process personal data in our Privacy Policy. Please state your consent ID and date when you contact us regarding your consent. [#OOI_PERSONAL_INFORMATION#] Deny Allow selection Customize OK Powered by Cookiebot by Usercentrics 2021 Year End Results Presentation Skip to content Group Sites * Africa Middle East * Ghana-Kama * Kenya-Beta Healthcare * Mauritius * MENAT * Nigeria * South Africa-Ethicare * South Africa-FCC * South Africa-HOLDINGS * South Africa-Nutritionals * South Africa-Pharmacare * Tanzania-Shelys * Americas * Brazil * Canada * Mexico * USA * Asia * China * Japan * Malaysia * Philippines * Taiwan * Australasia * Australia * New Zealand * Europe CIS * Austria * Czech Republic * France * France-NDB * Germany * Netherlands * Netherlands OSS * Netherlands-Aspen API * Russia * Slovakia * SPAIN * SWITZERLAND * Ghana-Kama * Kenya-Beta Healthcare * Mauritius * MENAT * Nigeria * South Africa-Ethicare * South Africa-FCC * South Africa-HOLDINGS * South Africa-Nutritionals * South Africa-Pharmacare * Tanzania-Shelys * Brazil * Canada * Mexico * USA * China * Japan * Malaysia * Philippines * Taiwan * Australia * New Zealand * Austria * Czech Republic * France * France-NDB * Germany * Netherlands * Netherlands OSS * Netherlands-Aspen API * Russia * Slovakia * SPAIN * SWITZERLAND OUR RESPONSE TO COVID-19 Menu * * About Aspen * * Group overview * Global presence * Board of Directors * * Group Executive Committee * History * Corporate governance and risk management * * Ethics & Compliance Management * Our response to COVID-19 * Close * Business Segments * * Regional Overviews * Africa Middle East * Americas * Asia * Australasia * Europe CIS * * * Sterile Focus Brands * Regional Brands * Manufacturing * * Manufacturing Capabilities * Close * Investor Relations * * Investor overview * SENS * Share price centre * * Shareholder centre * Investor Information * Supplementary documents * * Investor calendar * Close * We Care * * We Care Initiatives * We Care Videos * * Mandela Day * Responsible Corporate Citizenship * * Healthcare Heroes * Diversity & Inclusion * Close * Sustainability * * Sustainability overview * * Supplementary sustainability documents * * Close * Group News * * Group news * * Media coverage * * Close * Careers * * Working for Aspen * * Aspen jobs * * Close * Contact Us * * Contact form * * Contact details * * Global contact details * Close Menu * * About Aspen * * Group overview * Global presence * Board of Directors * * Group Executive Committee * History * Corporate governance and risk management * * Ethics & Compliance Management * Our response to COVID-19 * Close * Business Segments * * Regional Overviews * Africa Middle East * Americas * Asia * Australasia * Europe CIS * * * Sterile Focus Brands * Regional Brands * Manufacturing * * Manufacturing Capabilities * Close * Investor Relations * * Investor overview * SENS * Share price centre * * Shareholder centre * Investor Information * Supplementary documents * * Investor calendar * Close * We Care * * We Care Initiatives * We Care Videos * * Mandela Day * Responsible Corporate Citizenship * * Healthcare Heroes * Diversity & Inclusion * Close * Sustainability * * Sustainability overview * * Supplementary sustainability documents * * Close * Group News * * Group news * * Media coverage * * Close * Careers * * Working for Aspen * * Aspen jobs * * Close * Contact Us * * Contact form * * Contact details * * Global contact details * Close Integrated Report 2021 Click to view online Click to download Annual Financial Statements 2021 Click to download Integrated Report 2021 Click to view online Click to download Annual Financial Statements 2021 Click to download 2021 Integrated Report 2021 Annual Financial Statements ABOUT ASPEN Headquartered in Durban, South Africa, we are a global specialty and branded pharmaceutical company, improving the health of patients across the world through our high quality and affordable medicines. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability. With an acknowledged presence of more than two decades in the pharmaceutical sector, we improve the health of patients in more than 150 countries. The Group’s key business segments are Manufacturing and Commercial Pharmaceuticals comprising Regional Brands and Sterile Focus Brands. Group Overview REGISTER FOR ALERTS Register via Vault for alerts of SENS announcements, reports and event invitations. BOARD OF DIRECTORS -------------------------------------------------------------------------------- INVESTOR OVERVIEW -------------------------------------------------------------------------------- INVESTOR INFORMATION -------------------------------------------------------------------------------- SUSTAINABILITY DOCUMENTS GROUP NEWS ASPEN CONFIRMS NON-BINDING TERM SHEET ON MANUFACTURE AND SALE OF AN ASPEN- BRANDED COVID-19 VACCINE THROUGHOUT AFRICA 30 Nov 2021 Read More ASPEN WELCOMES KENYAN PRESIDENT UHURU KENYATTA TO ITS GQEBERHA MANUFACTURING SITE 24 Nov 2021 Read More MINISTER EBRAHIM PATEL OPENS ASPEN’S WORLD CLASS GENERAL ANAESTHETIC MANUFACTURING LINE 25 Oct 2021 Read More More Group News SENS ANNOUNCEMENTS MORE SENS INVESTOR CALENDAR 09 March 2022 Interim results SENS announcement 10 March 2022 Interim results presentation 15 March 2022 JP Morgan South African Healthcare Seminar (virtual) 29 March 2022 Bank of America Securities 23rd Annual Sun City Conference (virtual) 31 August 2022 Annual results SENS announcement 01 September 2022 Annual results presentation 12 September 2022 13th Annual RMB Morgan Stanley Big Five Investor Conference 08 December 2022 Annual General Meeting LATEST RESULTS 2021 Integrated reporting Aspen 2021 Integrated reporting * View online * PDF 30 MB Aspen 2021 Annual Financial Statements * PDF 1.2 MB Aspen 2021 Corporate Brochure * PDF 284 KB Year End results - 30 June 2021 Aspen Year End Results Presentation * PDF 9.7Mb Aspen reviewed provisional financial results for the year ended 30 June 2021 * PDF 147KB Aspen year end results short form announcement * PDF 67KB Aspen year end results webcast recording * Webcast More results More Group News MORE SENS Read more More results REGIONAL OVERVIEWS AFRICA MIDDLE EAST AMERICAS ASIA AUSTRALASIA EUROPE CIS AFRICA MIDDLE EAST AMERICAS ASIA AUSTRALASIA EUROPE CIS AFRICA MIDDLE EAST AMERICAS ASIA AUSTRALASIA EUROPE CIS AFRICA MIDDLE EAST AMERICAS ASIA AUSTRALASIA EUROPE CIS AFRICA MIDDLE EAST AMERICAS ASIA AUSTRALASIA EUROPE CIS AFRICA MIDDLE EAST This region represents the single largest revenue contributor in the Commercial Pharmaceuticals segment, with revenues predominantly from Regional Brands. Aspen supplies well-established local brands, as well as internationally recognised medicines across multiple countries in the region, supported by commercial and sales employees. Extensive and differentiated manufacturing capabilities including high potency and hormonal solids, vaccines and other state-of-the-art sterile capabilities exist at one of the Group’s primary manufacturing sites in Gqeberha, South Africa. This primary site is complemented by five regional sites across the continent. Key countries Egypt Kenya Kingdom of Saudi Arabia South Africa Tanzania Number of products launched: 48 (2020: 29) STATISTICS The South African private pharmaceutical sector was valued at R49,8 billion MAT* for the period ended July 2021. In South Africa, four out of the top 15 brands in the private sector were Aspen products. Source: IQVIA, IQVIA Midas 2021 and Market Prognosis Global. South Africa and Middle East and North Africa only. Sub-Saharan Africa (“SSA”) not covered by IQVIA *MAT = Moving annual total AMERICAS Aspen’s presence in the Americas is dominated by the businesses in Latin America. Mexico and Brazil are the largest contributors to regional performance. Aspen provides a range of trusted brands across prescription, hospital and over-the-counter medicines and operates one finished dose form manufacturing facility in Brazil. Key countries Brazil Canada Chile Colombia Ecuador Mexico USA Number of products launched: 3 (2020: 8) STATISTICS The Mexican pharmaceutical market grew 14,0% to USD10,8 billion MAT* June 2021, positively impacted by double-digit growth across the generic and ethical markets. Pharmaceutical sales across the total Spanish Latin America market grew 20% to USD21,3 billion MAT June 2021. Source: IQVIA – June 2021 *MAT = Moving annual total ASIA This region comprises all Asian territories where we sell products, including China. Active trading subsidiaries include those in China, the Philippines, Taiwan and Malaysia with other countries in the region reached via distributors. Sterile Focus Brands are the key contributor to revenue. Our manufacturing facility in India is our primary new product development site. Key countries China Malaysia Philippines Singapore Taiwan Number of products launched: 3 (2020: 1) STATISTICS The Chinese general anaesthesia therapy area consists of inhalation and intravenous products. The propofol market grew 10,6% year-on-year MAT* May 2021. The South Korean pharmaceutical market is forecast to grow at a CAGR of 6% between 2019 and 2024, reaching Won24,579 billion by 2024. Source: China IMS CHPA Report, May 2021. *MAT = Moving annual total Source: China IMS CHPA Report, May 2021. *MAT = Moving annual total AUSTRALASIA One of the largest pharmaceutical companies in the Australasia region, with a comprehensive portfolio of medicines comprising Regional Brands, including prescription and over-the-counter products, as well as Sterile Focus Brands. A widely-accredited manufacturing facility is operated in Australia, producing finished dose form solids, liquids and semi-solids as well as packaging for third party contract manufacturing for domestic and export markets. Key countries Australia New Zealand Number of products launched: 2 (2020: 2) STATISTICS The Australian and New Zealand pharmaceutical market combined, grew 1,9% and was valued at AUD20,7 billion MAT* to May 2021. Source: IQVIA – August 2020 *MAT = Moving annual total EUROPE CIS Europe CIS provides a broad range of Sterile Focus and Regional Brands while operating a range of manufacturing facilities for Aspen’s own production needs, as well as manufacturing for third parties. Sterile Focus Brands comprise anaesthetics and thrombosis in Russia and the other CIS countries only. Manufacturing activities include active pharmaceutical ingredients and finished dose form production and our sites are widely accredited. The prefilled syringe and multi-dose form sites in France and Germany respectively, provide finished dose form medicines for commercialisation by Aspen and third parties for both domestic and export markets. Key countries France Germany Netherlands Russian Federation United Kingdom Number of products launched: 1 (2020: Nil) STATISTICS AFRICA MIDDLE EAST This region represents the single largest revenue contributor in the Commercial Pharmaceuticals segment, with revenues predominantly from Regional Brands. Aspen supplies well-established local brands, as well as internationally recognised medicines across multiple countries in the region, supported by commercial and sales employees. Extensive and differentiated manufacturing capabilities including high potency and hormonal solids, vaccines and other state-of-the-art sterile capabilities exist at one of the Group’s primary manufacturing sites in Gqeberha, South Africa. This primary site is complemented by five regional sites across the continent. Key countries Egypt Kenya Kingdom of Saudi Arabia South Africa Tanzania Number of products launched: 48 (2020: 29) STATISTICS The South African private pharmaceutical sector was valued at R49,8 billion MAT* for the period ended July 2021. In South Africa, four out of the top 15 brands in the private sector were Aspen products. Source: IQVIA, IQVIA Midas 2021 and Market Prognosis Global. South Africa and Middle East and North Africa only. Sub-Saharan Africa (“SSA”) not covered by IQVIA *MAT = Moving annual total AMERICAS Aspen’s presence in the Americas is dominated by the businesses in Latin America. Mexico and Brazil are the largest contributors to regional performance. Aspen provides a range of trusted brands across prescription, hospital and over-the-counter medicines and operates one finished dose form manufacturing facility in Brazil. Key countries Brazil Canada Chile Colombia Ecuador Mexico USA Number of products launched: 3 (2020: 8) STATISTICS The Mexican pharmaceutical market grew 14,0% to USD10,8 billion MAT* June 2021, positively impacted by double-digit growth across the generic and ethical markets. Pharmaceutical sales across the total Spanish Latin America market grew 20% to USD21,3 billion MAT June 2021. Source: IQVIA – June 2021 *MAT = Moving annual total ASIA This region comprises all Asian territories where we sell products, including China. Active trading subsidiaries include those in China, the Philippines, Taiwan and Malaysia with other countries in the region reached via distributors. Sterile Focus Brands are the key contributor to revenue. Our manufacturing facility in India is our primary new product development site. Key countries China Malaysia Philippines Singapore Taiwan Number of products launched: 3 (2020: 1) STATISTICS The Chinese general anaesthesia therapy area consists of inhalation and intravenous products. The propofol market grew 10,6% year-on-year MAT* May 2021. The South Korean pharmaceutical market is forecast to grow at a CAGR of 6% between 2019 and 2024, reaching Won24,579 billion by 2024. Source: China IMS CHPA Report, May 2021. *MAT = Moving annual total Source: China IMS CHPA Report, May 2021. *MAT = Moving annual total AUSTRALASIA One of the largest pharmaceutical companies in the Australasia region, with a comprehensive portfolio of medicines comprising Regional Brands, including prescription and over-the-counter products, as well as Sterile Focus Brands. A widely-accredited manufacturing facility is operated in Australia, producing finished dose form solids, liquids and semi-solids as well as packaging for third party contract manufacturing for domestic and export markets. Key countries Australia New Zealand Number of products launched: 2 (2020: 2) STATISTICS The Australian and New Zealand pharmaceutical market combined, grew 1,9% and was valued at AUD20,7 billion MAT* to May 2021. Source: IQVIA – August 2020 *MAT = Moving annual total EUROPE CIS Europe CIS provides a broad range of Sterile Focus and Regional Brands while operating a range of manufacturing facilities for Aspen’s own production needs, as well as manufacturing for third parties. Sterile Focus Brands comprise anaesthetics and thrombosis in Russia and the other CIS countries only. Manufacturing activities include active pharmaceutical ingredients and finished dose form production and our sites are widely accredited. The prefilled syringe and multi-dose form sites in France and Germany respectively, provide finished dose form medicines for commercialisation by Aspen and third parties for both domestic and export markets. Key countries France Germany Netherlands Russian Federation United Kingdom Number of products launched: 1 (2020: Nil) STATISTICS * © 2022 Aspen Holdings * Disclaimer * Privacy Statement * Aspen PAIA & POPI Manual * Standard Terms of purchase of goods or services (STC) * Contact details * Designed & Produced by Bastion Graphics * Africa Middle East * Ghana-Kama * Kenya-Beta Healthcare * Mauritius * MENAT * Nigeria * South Africa-Ethicare * South Africa-FCC * South Africa-HOLDINGS * South Africa-Nutritionals * South Africa-Pharmacare * Tanzania-Shelys * Americas * Brazil * Canada * Mexico * USA * Asia * China * Japan * Malaysia * Philippines * Taiwan * Australasia * Australia * New Zealand * Europe CIS * Austria * Czech Republic * France * France-NDB * Germany * Netherlands * Netherlands OSS * Netherlands-Aspen API * Russia * Slovakia * SPAIN * SWITZERLAND * Ghana-Kama * Kenya-Beta Healthcare * Mauritius * MENAT * Nigeria * South Africa-Ethicare * South Africa-FCC * South Africa-HOLDINGS * South Africa-Nutritionals * South Africa-Pharmacare * Tanzania-Shelys * Brazil * Canada * Mexico * USA * China * Japan * Malaysia * Philippines * Taiwan * Australia * New Zealand * Austria * Czech Republic * France * France-NDB * Germany * Netherlands * Netherlands OSS * Netherlands-Aspen API * Russia * Slovakia * SPAIN * SWITZERLAND You are not a HCP so we cannot give you access to the products × Are you health care professional? Yes No × Are you health care professional? Yes No × Are you health care professional? Yes No × Are you health care professional? Yes No × Are you health care professional? Yes No × Are you health care professional? Yes No × Are you health care professional? Yes No × Are you health care professional? Yes No × Scroll To Top